Compare · EARS vs KIN
EARS vs KIN
Side-by-side comparison of Auris Medical Holding Ltd. (EARS) and Kindred Biosciences, Inc. (KIN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EARS and KIN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KIN carries a market cap of $420.5M.
- Company
- Auris Medical Holding Ltd.
- Kindred Biosciences, Inc.
- Price
- $3.07-0.65%
- $9.25+0.00%
- Market cap
- -
- $420.5M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2013
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 0
Kindred Biosciences, Inc.
Kindred Biosciences, Inc., a commercial-stage biopharmaceutical company, engages in developing therapies for pets. Its product pipeline focuses on biologics for a range of indications primarily in dogs and cats. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats; and Zimeta, a dipyrone injection for the control of fever in horses. It also develops KIND-016, a monoclonal antibody for the treatment of atopic dermatitis in dogs; KIND-032, a monoclonal antibody targeting interleukin-4 (IL-4) receptor for the treatment of atopic dermatitis in dogs; KIND-025 a canine fusion protein targeting IL-4 and IL-13 for atopic dermatitis in dogs; KIND-030, a monoclonal antibody targeting canine parvovirus for the prophylactic indication in dogs; KIND-509, an antibody for canine inflammatory bowel disease in dogs; KIND-510a, a long-acting feline recombinant erythropoietin being developed for the management of non-regenerative anemia in cats; and KIND-511, an anti-tumor necrosis factor treatment for newborn foals. The company was incorporated in 2012 and is headquartered in Burlingame, California.
Latest EARS
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2
- Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology
- Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany
- Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- SEC Form EFFECT filed by Auris Medical Holding Ltd.
- SEC Form 6-K filed by Auris Medical Holding Ltd.
- Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning
Latest KIN
- TCW Special Purpose Acquisition Corp. Appoints Nanxi Liu to Board of Directors
- SEC Form SC 13G/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4 filed by Park West Asset Management Llc
- SEC Form 15-12B filed by Kindred Biosciences, Inc.
- SEC Form EFFECT filed by Kindred Biosciences, Inc.
- SEC Form SC 13D/A filed by Kindred Biosciences, Inc. (Amendment)
- SEC Form 4: Chin Richard returned $15,884,757 worth of Common Stock to the company (1,717,271 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Wee Wendy returned $727,170 worth of Common Stock to the company (78,613 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Bevers Denise returned $1,348,974 worth of Common Stock to the company (145,835 units at $9.25), closing all direct ownership in the company
- SEC Form 4: Zhan Hangjun returned $594,830 worth of Common Stock to the company (64,306 units at $9.25), closing all direct ownership in the company